Charlie Aitken, MD at Bell Potter, stands by GI Dynamics (ASX:GID) and its plan to raise A$35.0mm in a private placement to fund the US FDA pivotal trail of...

Charlie Aitken, MD at Bell Potter, stands by GI Dynamics (ASX:GID) and its plan to raise A$35.0mm in a private placement to fund the US FDA pivotal trail of its EndoBarrier product. He says that EndoBarrier targets a massive end market of global diabetes and obesity patients. The product has delivered proven results and attracted major shareholders such as Johnson & Johnson and Medtronic which have invested in this small-cap developer of healthcare technology. As the US spends $200-300bn annually on obesity/diabetes treatment, GID would only need a tiny percentage of that market to potentially be worth multiples of 53c.


MORE ON



2 topics

Livewire News brings you a wide range of financial insights with a focus on Global Macro, Fixed Income, Currencies and Commodities.

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.